Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CA3 | P07451 | 1/20 | 0.44 |
| ▸ | CA4 | P22748 | 1/20 | 0.44 |
| ▸ | CA6 | P23280 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | CA5A | P35218 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL57877 | 0.76 | CA12 (0.48) | CA12CA1CA2LMNACA3 | |
| SCHEMBL496601 | 0.74 | HIF1A (0.65) | HIF1A | |
| SCHEMBL8103815 | 0.73 | CA12 (0.46) | CA12CA1CA2LMNACA3 | |
| SCHEMBL4930668 | 0.73 | CA12 (0.46) | CA12CA1CA2LMNACA3 | |
| SCHEMBL2874811 | 0.71 | CA12 (0.44) | CA12CA1CA2LMNACA3 | |
| SCHEMBL468359 | 0.71 | ESR1 (0.53) | CA12CA1CA2LMNACA3 | |
| SCHEMBL6419652 | 0.71 | CA12 (0.44) | CA12CA1CA2LMNACA3 | |
| SCHEMBL1887460 | 0.71 | CA12 (0.48) | CA12CA1CA2LMNACA3 | |
| SCHEMBL210393 | 0.71 | HIF1A (0.47) | CA12CA1CA2LMNACA3 | |
| SCHEMBL30330201 | 0.71 | SMN1; SMN2 (0.45) | CA12CA1CA2LMNACA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 212 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357255-A1 | IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS | INCYTE CORPORATION | 2023-11-09 | — | — | US | claimed |
| US-11673894-B2 | Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors | INCYTE CORPORATION (US) | 2023-06-13 | — | — | US | claimed |
| US-20210139485-A1 | IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS | INCYTE CORPORATION | 2021-05-13 | — | — | US | claimed |
| CN-112384515-A | Imidazopyrimidines and triazolopyrimidines as A2A/A2B inhibitors | 因赛特公司 | 2021-02-19 | — | — | CN | claimed |
| CN-109574944-B | Isoxazoline derivatives and their use in agriculture | 东莞市东阳光农药研发有限公司 | 2019-12-27 | — | — | CN | claimed |
| US-20190292188-A1 | IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS | INCYTE CORPORATION | 2019-09-26 | — | — | US | claimed |
| US-20140057901-A1 | XANTHINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2014-02-27 | — | — | US | claimed |
| EP-2298769-B1 | Xanthin derivatives, their production and utilisation as medicine | BOEHRINGER INGELHEIM PHARMA (DE) | 2013-10-30 | — | — | EP | claimed |
| US-20130165428-A1 | XANTHINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2013-06-27 | — | — | US | claimed |
| US-20120252783-A1 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA & CO. KG (DE) | 2012-10-04 | — | — | US | claimed |
| CN-1120041-A | Novel benzobiulkyl, preparation of same and parmaceutical composition of same | ADIEL COMPANY (FR) | 1996-04-10 | — | — | CN | claimed |
| US-5500443-A | SCHIZOPHRENIA | ADIR ET COMPAGNIE (FR) | 1996-03-19 | — | — | US | claimed |
| WO-1996000708-A1 | METHOD FOR PREPARING ALKYLATING AGENTS AND THEIR USE FOR ALKYLATING CYCLIC UREAS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-01-11 | — | — | WO | claimed |
| EP-0686151-A1 | SUBSTITUTED CYCLIC CARBONYLS AND DERIVATIVES THEREOF USEFUL AS RETROVIRAL PROTEASE INHIBITORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-12-13 | — | — | EP | claimed |
| EP-0669331-A1 | Benzodioxane derivatives, process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1995-08-30 | — | — | EP | claimed |
| WO-1994019329-A1 | SUBSTITUTED CYCLIC CARBONYLS AND DERIVATIVES THEREOF USEFUL AS RETROVIRAL PROTEASE INHIBITORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-09-01 | — | — | WO | claimed |
| EP-0201221-B1 | 6-(1-ACYL-1-HYDROXY METHYL) PENICILLANIC ACID DERIVATIVES | PFIZER INC. (US) | 1990-08-01 | — | — | EP | claimed |
| US-4762921-A | 6-(1-acyl-1-hydroxymethyl)penicillanic acid derivatives | PFIZER INC. (US) | 1988-08-09 | — | — | US | claimed |
| US-4675186-A | 6-(1-acyl-1-hydroxymethyl)penicillanic acid derivatives | PFIZER INC. (US) | 1987-06-23 | — | — | US | claimed |
| EP-0201221-A1 | 6-(1-acyl-1-hydroxy methyl) penicillanic acid derivatives | PFIZER INC. (US) | 1986-11-12 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165428-A1 | XANTHINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | DPP4, DPP3, DPP7 | CA12 1986/4885CA1 1053/4885CA2 1054/4885 |
| US-20210139485-A1 | IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS | ADORA2A, ADORA2B, ADORA1 | CA12 4643/4885CA1 3900/4885CA2 2216/4885 |
| US-20120252783-A1 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | DPP4, DPP3, DPP7 | CA12 2049/4885CA1 1316/4885CA2 1293/4885 |
| US-20190292188-A1 | IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS | ADORA2A, ADORA2B, ADORA1 | CA12 4643/4885CA1 3900/4885CA2 2216/4885 |
| US-20230357255-A1 | IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS | ADORA2A, ADORA2B, ADORA1 | CA12 4643/4885CA1 3900/4885CA2 2216/4885 |
| US-20140057901-A1 | XANTHINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | DPP4, DPP3, DPP7 | CA12 2049/4885CA1 1316/4885CA2 1293/4885 |
| US-11673894-B2 | Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors | ADORA2A, ADORA2B, ADORA1 | CA12 4643/4885CA1 3900/4885CA2 2216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.